Northern Trust Corp Purchases 120,785 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Northern Trust Corp increased its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,532,929 shares of the biopharmaceutical company's stock after buying an additional 120,785 shares during the period. Northern Trust Corp owned about 0.98% of TG Therapeutics worth $46,141,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of TGTX. Arizona State Retirement System raised its position in shares of TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. increased its position in shares of TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares in the last quarter. Summit Investment Advisors Inc. increased its position in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 463 shares in the last quarter. Brookstone Capital Management grew its position in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after purchasing an additional 624 shares in the last quarter. Finally, Daymark Wealth Partners LLC increased its stake in TG Therapeutics by 1.7% in the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after buying an additional 689 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Up 4.0%

Shares of NASDAQ:TGTX traded up $1.35 during mid-day trading on Monday, reaching $34.99. The stock had a trading volume of 2,839,383 shares, compared to its average volume of 3,021,399. The firm has a market cap of $5.56 billion, a PE ratio of -349.87 and a beta of 2.21. The firm has a 50 day simple moving average of $38.90 and a two-hundred day simple moving average of $33.70. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's quarterly revenue was up 90.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.07) earnings per share. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on TGTX shares. HC Wainwright reiterated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.